No products in the cart.
Pre-made Abrilumab benchmark antibody ( Whole mAb, anti-¦Á4¦Â7/Integrin alpha 4 beta 7 therapeutic antibody, Anti-LPAM?1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-005
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Abrilumab biosimilar, Whole mAb, Anti-¦Á4¦Â7/Integrin alpha 4 beta 7 Antibody: Anti-LPAM?1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Abrilumab (INN; development code AMG 181) is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn’s disease.This drug was developed by MedImmune.
| Products Name (INN Index) | Pre-Made Abrilumab biosimilar, Whole mAb, Anti-¦Á4¦Â7/Integrin alpha 4 beta 7 Antibody: Anti-LPAM?1 therapeutic antibody |
|---|---|
| INN Name | Abrilumab |
| Target | ¦Á4¦Â7 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | Amgen,AstraZeneca |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Crohn's disease,Ulcerative colitis |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | α4β7/Integrin alpha 4 beta 7 |
| Package |
Previous slide
Next slide
